



SARTORIUS

Sartorius Sponsored Symposium

Sunday 23 June 2024

13:30 – 15:00

Room – Kilsyth

Driving Performance, Scalability, and a Simplified Path to Cell & Gene Therapy Commercialization

The ability of cell and gene therapies to improve patient lives has been clearly demonstrated with the successful approval of over 65 products globally. In 2023 alone we saw 6 approvals for gene and gene-modified cell therapies, signaling rapid growth and a promising future. These clinical successes motivate therapy developers to hasten market entry, yet the challenge remains to develop high-quality, safe products with reduced cost per dose. The industry is actively looking for more effective development processes—processes built to consistently perform, seamlessly scale, and adhere to complex and evolving regulatory requirements. These factors set the stage for a simplified path to commercialization, but how can early-stage developers balance today's demands while getting prepared for future clinical success? In this workshop, hear from a diverse panel of experts from across industry—from University to CDMO—on the novel approaches and innovative technologies that are pushing the boundaries of CGT development and manufacturing to drive performance, scalability, and regulatory compliance. Following short individual presentations, our distinguished speakers will gather to discuss key challenges, considerations, and the future outlook on this dynamic field.

Moderator:

Lorraine Borland, Senior Expert Bioprocess Solutions, Cell & Gene, Sartorius

Speakers:

Pierre Springuel, PBioChemEng PhD Candidate, University College London

Klaus Graumann, CEO Phoenestra GmbH

Ahmed Youssef, Senior Manager USP, Ascend Advanced Therapies

Harm Niederländer, Platform Development Specialist, Sartorius